| |
Patients (N = 216) in NEOZOTAC
|
|---|
|
Median age, years (range)
| |
49.5 (28–70)
|
|
Median BMI, kg/m2 (range)
| |
26.2 (18.3–42.0)
|
|
Clinical T stage
|
cT1 or cT2
|
123 (56.9 %)
|
| |
cT3 or cT4
|
93 (43.1 %)
|
|
Clinical N stage
|
cN0
|
101 (46.8 %)
|
| |
cN+
|
115 (53.2 %)
|
|
Tumor type
|
Ductal
|
128 (59.3 %)
|
| |
Lobular
|
38 (17.6 %)
|
| |
Other
|
18 (8.4 %)
|
| |
Unknown
|
32 (14.8 %)
|
|
HR status
|
ER+ and/or PR+
|
180 (83.3 %)
|
| |
ER– and PR–
|
36 (16.7 %)
|
|
Allocated treatment
|
TAC
|
109 (50.5 %)
|
| |
TAC + ZA
|
107 (49.5 %)
|
|
pCR breast and LN
|
Yes
|
25 (11.6 %)
|
| |
No
|
184 (85.2 %)
|
| |
Unknown
|
7 (3.2 %)
|
|
MP breast
|
1
|
33 (15.3 %)
|
| |
2
|
56 (25.9 %)
|
| |
3
|
41 (19.0 %)
|
| |
4
|
42 (19.4 %)
|
| |
5
|
35 (16.2 %)
|
| |
Unknown
|
9 (4.2 %)
|
-
BMI body mass index, ER estrogen receptor, HR hormone receptor, LN lymph nodes, MP Miller and Payne, pCR pathologic complete response, PR progesterone receptor, TAC docetaxel, doxorubicin, and cyclophosphamide, ZA zoledronic acid
